Wednesday, December 3, 2014

Genzyme's LEMTRADA Approved by the FDA

On November 14, 2014 a new MS treatment was approved for RRMS by the FDA.  It is called LEMTRADA and it is from Genzyme

The first treatment for MS was not approved until 1993.  I was a sophomore in high school then (I know it is hard for me to believe too)!  Imagine if I had been diagnosed while still in high school.  My treatment options would have been. . . well option-less.

Now a little over 20 years later there are twelve treatment options!  Maybe even more exciting is that is the past several years three oral treatment options have been approved including the treatment I am now on, Gilenya.  When I was diagnosed in 2008 my only treatment options were injections which I did for five years!  I'm so much happier to be popping a pill now.  You can read about my first dose experience here and my update one year later here.

Below is a list of all the approved treatments, the pharmaceutical company and year approved.

A little more about LEMTRADA. . . it is an IV infusion given initially for five consecutive days and then a year later for three days.  That is it!  It is different from anything else on the market.  It does say that only people who have responded poorly to two or more other treatments should use LEMTRADA.  That means it isn't an option for me right now (since I've only  had issues with one treatment, Tecfidera) not that I'm even considering changing treatments right now.  Good to know if Gilenya stops working for me there are other options out there besides going back to injections.

For more information about LEMTRADA (all the technical stuff) check out this article on the National MS Society's website.

Disclaimer:  This is NOT a sponsored post.  Genzyme doesn't even know I'm writing it! These are my own thoughts/opinions and you should always talk to your doctor about the best treatment option for you.


1 comment:

  1. Wow that's awesome-- annual hookups to an IV? That sounds like a great system! Glad that what you're currently on is working so well though.